India  

Bharat Biotech

Indian biotechnology company and vaccine manufacturer

Bharat Biotech    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Bharat Biotech: Indian biotechnology company and vaccine manufacturer
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

0
shares
ShareTweetSavePostSend
 

You Might Like


Covaxin supply to hit 5.5 cr doses from October: Bharat Biotech chairman

Covaxin output is all set to be ramped up to 5.5 crore doses in October from to 3.5 crore doses in September, Bharat Biotech’s chairman & managing director Dr Krishna Ella said on Tuesday. Pointing..
IndiaTimes - Published

Covaxin kids trial over, Bharat Biotech to submit data to DCGI next week


IndiaTimes - Published

Covaxin may soon get WHO approval as expert group scheduled to meet next month

SAGE members and Bharat Biotech officials will hold a meeting where safety and efficacy of Covaxin will be discussed on the basis trial data in India.
DNA - Published

Bharat Biotech awaits feedback from WHO for Covid-19 vaccine Covaxin's emergency use listing


IndiaTimes - Published

AIIMS Delhi to conduct phase 2/3 clinical trials for Bharat Biotech's nasal COVID vaccine

Delhi AIIMS is one of the three hospitals where the phase 2 and 3 trials of Bharat Biotech's intranasal vaccine will be conducted.
DNA - Published Also reported by •IndiaTimes

First batch of Covaxin rolls out of Gujarat plant of Bharat Biotech


IndiaTimes - Published

First commercial batch of Covaxin rolls out from Bharat Biotech's Ankleshwar plant

In a move that will augment the supply of indigenously developed Covid-19 vaccine Covaxin, Bharat Biotech on Sunday announced the rollout of the first commercial batch of Covaxin from its Chiron..
IndiaTimes - Published

1 Covaxin dose to survivor equals 2 doses to uninfected

A single-dose of Bharat Biotech’s Covaxin in people who had been infected with Covid-19 previously generates antibody response similar to that provided by two doses of the vaccine in those without..
IndiaTimes - Published

Covid vaccination for kids may start only by March ’22

Zydus Cadila's Covid-19 vaccine, ZyCoV-D, is expected to get an emergency use authorisation for the 12-18 cohort by end of August, whereas Bharat Biotech’s Covaxin – the world’s only vaccine..
IndiaTimes - Published

Bharat Biotech's intransal Covid vaccine gets nod for phase II/III trials


IndiaTimes - Published

75 million Covaxin doses supplied, more by September, says Bharat Biotech's Suchitra Ella


IndiaTimes - Published

Union health minister Mansukh Mandaviya meets WHO Chief Scientist Dr Soumya Swaminathan, discusses WHO's approval of Covaxin

Union health minister Mansukh Mandaviya on Thursday met World Health Organization (WHO) Chief Scientist Dr Soumya Swaminathan and held a discussion over the world body's approval of Bharat Biotech's..
IndiaTimes - Published

Govt approves Bharat Biotech's Ankleshwar plant for manufacturing Covaxin

Union health minister Mansukh Mandaviya on Tuesday said the government has approved Bharat Biotech’s vaccine manufacturing facility at Ankleshwar in Gujarat for manufacturing India’s first..
IndiaTimes - Published

136 crore Covishield, Covaxin doses to lead India's vaccination drive during August-December

More than 136 crore Covid-19 vaccine doses are expected to be available till the end of this year, informed the Centre. For the next four months, India's vaccine programme will be accelerated by the..
IndiaTimes - Published

Bharat Biotech issues clarification on quality concerns with Covaxin

The statement came after reports that test batches of Covaxin were not satisfactory and got rejected leading to delayed production.
DNA - Published

Covaxin output set to rise; govt hopes to meet 135 crore-dose goal

Indian Immunologicals Limited is likely to start supply of an additional 2 million doses of Covaxin from August-September, whereas Bharat Biotech’s Ankleshwar facility is likely to add 6 million..
IndiaTimes - Published

Brazil's Anvisa provisionally suspends authorisation for exceptional import of 4 million Covaxin doses

After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa (Agencia Nacional de Vigilancia Sanitaria)..
IndiaTimes - Published

Brazil suspends Bharat Biotech imports permit


IndiaTimes - Published

After suspending Covaxin clinical trials, Brazil closes EUA request

After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s health regulator Anvisa (Agencia Nacional..
IndiaTimes - Published

Bharat Biotech terminates pact with Brazil partners Precisa Medicamentos, Envixia Pharma


IndiaTimes - Published

Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programme

Bharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme.
IndiaTimes - Published

AIIMS to begin second dose trial of Bharat Biotech's Covaxin on children between 2-6 years

Not just Bharat Biotech's Covaxin but Zydus Cadila's vaccine for children is also currently under trial in India
DNA - Published

Bharat Biotech dossier under review for Covaxin emergency use listing: WHO


IndiaTimes - Published

Submitted all required documents to WHO for EUL: Bharat Biotech


IndiaTimes - Published

WHO Chief Scientist Dr Swaminathan says phase-3 trials of Covaxin look good, Bharat Biotech awaits approval

A few days ago, Bharat Biotech had released the phase 3 clinical trial results of Covaxin after evaluating 130 symptomatic COVID-19 cases.
DNA - Published

Covaxin's overall efficacy 77.8%, 65.2% effective against Delta variant: Bharat Biotech


IndiaTimes - Published

Bharat Biotech says vaccine 93.4% effective against severe Covid-19

Phase-III trials of Covaxin, made by Hyderabad's Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The data demonstrated 65.2% protection..
IndiaTimes - Published

Inching towards WHO's emergency use approval for Covaxin: Bharat Biotech


IndiaTimes - Published

Bharat Biotech denies receiving advance payments, supplying vaccines to Brazil


IndiaTimes - Published

Bharat Biotech slams allegations of wrongdoing in Covaxin procurement deal in Brazil


IndiaTimes - Published

Brazil suspends Bharat Biotech s Covaxin order over graft allegations


IndiaTimes - Published

Bharat Biotech chairman given central security cover


IndiaTimes - Published

'Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trials'

Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee..
IndiaTimes - Published

Bharat Biotech has submitted Covaxin's Phase III trial data to DCGI: Govt sources


IndiaTimes - Published

Covid-19: WHO accepts expression of interest for Covaxin emergency use listing

Covaxin has inched a step closer to a World Health Organization (WHO) emergency use listing (EUL) with the global body accepting Bharat Biotech’s expression of interest (EoI) for the inactivated..
IndiaTimes - Published

Bharat Biotech, WHO pre-submission meeting on June 23: WHO

Hyderabad-based Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use Listing (EUL) of its indigenous COVID-19..
IndiaTimes - Published

Covaxin does not contain newborn calf serum, say Bharat Biotech and govt


IndiaTimes - Published

Fact Check: No newborn calf serum in Covaxin, Health Ministry and Bharat Biotech confirm

The final vaccine does not contain newborn calf serum at all as the calf serum is not an ingredient of the final vaccine product, Health Ministry said
DNA - Published

Covaxin does not contain newborn calf serum: Centre busts myths

The indigenously developed Covaxin does not contain newborn calf serum, clarified Centre on Wednesday. The statement came in response to some social media posts which the government said have "twisted..
IndiaTimes - Published

SII, Bharat Biotech seek hike in government price for Covid vaccines

Serum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield and Covaxin shots in private hospitals..
IndiaTimes - Published

Bharat Biotech says Rs 150 per Covaxin dose to government not sustainable

The vaccine maker has said that it had to invest over Rs 500 crore at risk from its resources for product development, clinical trials, manufacturing.
DNA - Published

Covaxin average price realisation less than Rs 250 per dose: Bharat Biotech


IndiaTimes - Published

CISF takes over security of Bharat Biotech plant


IndiaTimes - Published

CISF takes over security of Covaxin manufacturer Bharat Biotech's Hyderabad campus


IndiaTimes - Published

Covaxin maker Bharat Biotech gets CISF cover of 64 personnel


IndiaTimes - Published

Can person with any allergy take COVID-19 shots? Know what experts say

Bharat Biotech, the manufacturer of the COVID-19 vaccine said that those who have known allergies to any component of Covaxin should not take the jab.
DNA - Published

Committed to data transparency on Covaxin, published 9 papers in 12 months: Bharat Biotech


IndiaTimes - Published

Ocugen to seek emergency nod for Covaxin from Health Canada

Bharat Biotech’s US partner Ocugen said it will be seeking an emergency use nod for India’s first indigenously developed Covid-19 vaccine Covaxin from the Canadian health authorities. The company..
IndiaTimes - Published

Ocugen to seek full approval for Covaxin in US via BLA instead of EUA

Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application..
IndiaTimes - Published

Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for Canada

Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application..
IndiaTimes - Published


 Page 1  〉